Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences
Cognition Therapeutics (NASDAQ: CGTX), a clinical-stage company developing drugs for neurodegenerative disorders, announced its participation in two upcoming investor conferences in September 2024. CEO Lisa Ricciardi will attend the Chardan Capital Markets Leadership Call on September 5 and the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11.
The company recently presented results from the Phase 2 SHINE study, showing that their orally delivered CT1812 slowed the progression of mild-to-moderate Alzheimer's disease after six months of treatment. Cognition is advancing its clinical programs for CT1812 in Alzheimer's disease, with the SHIMMER Phase 2 study readout expected by year-end 2024. Archived webcasts of the presentations will be available on Cognition's investor relations site.
Cognition Therapeutics (NASDAQ: CGTX), un'azienda in fase clinica che sviluppa farmaci per disturbi neurodegenerativi, ha annunciato la sua partecipazione a due prossime conferenze per investitori a settembre 2024. La CEO Lisa Ricciardi parteciperà alla Chardan Capital Markets Leadership Call il 5 settembre e alla H.C. Wainwright 26th Annual Global Investment Conference dal 9 all'11 settembre.
L'azienda ha recentemente presentato i risultati dello studio SHINE di Fase 2, dimostrando che il loro trattamento orale CT1812 ha rallentato la progressione della malattia di Alzheimer da lieve a moderata dopo sei mesi di trattamento. Cognition sta avanzando i suoi programmi clinici per CT1812 nella malattia di Alzheimer, con i risultati dello studio SHIMMER di Fase 2 previsti entro la fine del 2024. I webcast archiviati delle presentazioni saranno disponibili nel sito delle relazioni con gli investitori di Cognition.
Cognition Therapeutics (NASDAQ: CGTX), una empresa en etapa clínica que desarrolla medicamentos para trastornos neurodegenerativos, anunció su participación en dos próximas conferencias para inversionistas en septiembre de 2024. La CEO Lisa Ricciardi asistirá a la Chardan Capital Markets Leadership Call el 5 de septiembre y a la H.C. Wainwright 26th Annual Global Investment Conference del 9 al 11 de septiembre.
La empresa presentó recientemente los resultados del estudio SHINE de Fase 2, que muestran que su tratamiento oral CT1812 ralentizó la progresión de la enfermedad de Alzheimer leve a moderada tras seis meses de tratamiento. Cognition está avanzando sus programas clínicos para CT1812 en la enfermedad de Alzheimer, con los resultados del estudio SHIMMER de Fase 2 previstos para finales de 2024. Las presentaciones archivadas en formato webcast estarán disponibles en el sitio de relaciones con inversionistas de Cognition.
Cognition Therapeutics (NASDAQ: CGTX)는 신경퇴행성 질환 치료제를 개발하는 임상 단계 회사로, 2024년 9월에 예정된 두 개의 투자자 회의에 참석할 것이라고 발표했습니다. CEO 리사 리차르디는 9월 5일 차단 캐피탈 마켓 리더십 콜과 9월 9일부터 11일까지 H.C. 웨인라이트 제26회 연례 글로벌 투자 회의에 참석할 예정입니다.
회사는 최근 2상 SHINE 연구의 결과를 발표했으며, 이를 통해 경증에서 중등증 알츠하이머병 환자에게 CT1812를 경구 투여했을 때 치료 6개월 후 질병의 진행이 지연되었다고 밝혔습니다. Cognition은 알츠하이머병에 대한 CT1812의 임상 프로그램을 진행하고 있으며, SHIMMER 2상 연구의 결과는 2024년 말까지 예정되어 있습니다. 발표의 아카이브 웹캐스트는 Cognition의 투자자 관계 사이트에서 확인할 수 있습니다.
Cognition Therapeutics (NASDAQ: CGTX), une entreprise en phase clinique développant des médicaments pour les troubles neurodégénératifs, a annoncé sa participation à deux conférences pour investisseurs à venir en septembre 2024. La CEO Lisa Ricciardi assistera à la Chardan Capital Markets Leadership Call le 5 septembre et à la H.C. Wainwright 26th Annual Global Investment Conference du 9 au 11 septembre.
L'entreprise a récemment présenté les résultats de l'étude SHINE de Phase 2, montrant que leur traitement oral CT1812 a ralenti la progression de la maladie d'Alzheimer de légère à modérée après six mois de traitement. Cognition fait progresser ses programmes cliniques pour CT1812 dans la maladie d'Alzheimer, avec les résultats de l'étude SHIMMER de Phase 2 attendus d'ici la fin 2024. Les webinaires archivés des présentations seront disponibles sur le site des relations avec les investisseurs de Cognition.
Cognition Therapeutics (NASDAQ: CGTX), ein Unternehmen in der klinischen Phase, das Medikamente für neurodegenerative Erkrankungen entwickelt, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2024 bekannt gegeben. CEO Lisa Ricciardi wird am 5. September an der Chardan Capital Markets Leadership Call und vom 9. bis 11. September an der H.C. Wainwright 26th Annual Global Investment Conference teilnehmen.
Das Unternehmen hat kürzlich die Ergebnisse der Phase 2 SHINE-Studie präsentiert, die zeigen, dass ihr oral verabreichtes CT1812 das Fortschreiten der milden bis moderaten Alzheimer-Krankheit nach sechsmonatiger Behandlung verlangsamte. Cognition entwickelt seine klinischen Programme für CT1812 bei der Alzheimer-Krankheit weiter, mit der SHIMMER Phase 2-Studienauswertung, die bis Ende 2024 erwartet wird. Archivierte Webcasts der Präsentationen sind auf der Investor Relations-Website von Cognition verfügbar.
- None.
- None.
PURCHASE, N.Y., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced the Company’s president and CEO, Lisa Ricciardi will participate in two investor conferences in September.
September 2024 Investor Conferences
Event: Chardan Capital Markets Leadership Call
Date/Time: September 5, 2024, at 11:00am ET
Livestream: Individuals interested in attending the live virtual event can email corpaccess@chardan.com
Event: H.C. Wainwright 26th Annual Global Investment Conference
Date/Time: September 9-11, 2024
Webcast: Available On-Demand beginning September 9th at 7:00am ET
“We recently presented results from the Phase 2, proof-of-concept, SHINE study showing our orally delivered CT1812 slowed the progression of mild-to-moderate Alzheimer’s disease after just six months of treatment,” said CEO Lisa Ricciardi. “These upcoming events provide important opportunities to engage with investors as we advance our clinical programs for CT1812 in Alzheimer’s disease, with the SHIMMER Phase 2 study readout expected by year-end 2024.”
Archived webcasts of these presentations will be available on the “events and presentations” section of Cognition’s investor relations site.
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc., is discovering and developing first-in-class small molecule therapeutics targeting degenerative disorders of the central nervous system and retina. Our lead candidate CT1812 is in multiple clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB), and dry age-related macular degeneration (dry AMD). We believe CT1812 can regulate pathways that are impaired in these diseases. More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release or made during the conference, excluding statements of historical facts and statements related to current conditions, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results to be materially different from any future. In some cases, you can identify forward-looking statements by terms such as “may,” might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. You should not rely on these forward-looking statements as predictions of future events. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities and costs related thereto; uncertainties related to the conduct and results of clinical trials; the timing, scope and likelihood of regulatory filings and regulatory approvals of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; the evolution of the markets in which we compete; our ability to implement our continue to innovate; our ability to defend our intellectual property; impacts of ongoing global and regional conflicts; supply chain and labor force; and the risks and uncertainties described more fully in the “Risk Factors” section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at www.sec.gov. New risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties that we may face. Consider such risk factors carefully when considering Cognition Therapeutics’ prospects. Any forward-looking statements represent Cognition Therapeutics’ beliefs and assumptions only as of the date of this press release and September conference presentations. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
| Contact Information: Cognition Therapeutics, Inc. info@cogrx.com | Casey McDonald (media) Tiberend Strategic Advisors, Inc. cmcdonald@tiberend.com | Mike Moyer (investors) LifeSci Advisors mmoyer@lifesciadvisors.com |
FAQ
What investor conferences will Cognition Therapeutics (CGTX) participate in during September 2024?
What were the results of Cognition Therapeutics' (CGTX) Phase 2 SHINE study for CT1812?
When is the expected readout for Cognition Therapeutics' (CGTX) SHIMMER Phase 2 study?
How can investors access Cognition Therapeutics' (CGTX) conference presentations?
